Edwards Follows Guidant’s Exit From AAA Market, Seeks Lifepath Acquirer
This article was originally published in The Gray Sheet
Executive Summary
Edwards Lifesciences' decision to suspend its Lifepath endovascular graft program accompanies a realignment of R&D priorities to cope with the rapidly maturing AAA market
You may also be interested in...
Edwards scraps AAA program
Edwards Lifesciences' inability to find a buyer for its LifePath aortic aneurysm endovascular graft system will lead to termination of the program, the company says. The only firms with endovascular surgery sales forces capable of supporting LifePath already offer AAA grafts or are developing them, Edwards explains. The company announced its intention to exit the AAA business in December (1"The Gray Sheet" Dec. 15, 2003, p. 7). European sales will end in June. Edwards says it will complete patient follow-up for a U.S. study which closed enrollment in January...
Edwards scraps AAA program
Edwards Lifesciences' inability to find a buyer for its LifePath aortic aneurysm endovascular graft system will lead to termination of the program, the company says. The only firms with endovascular surgery sales forces capable of supporting LifePath already offer AAA grafts or are developing them, Edwards explains. The company announced its intention to exit the AAA business in December (1"The Gray Sheet" Dec. 15, 2003, p. 7). European sales will end in June. Edwards says it will complete patient follow-up for a U.S. study which closed enrollment in January...
Medtronic Tests Talent For U.S. Thoracic Aortic Aneurysm Market
Medtronic is projecting that its Talent thoracic aortic aneurysm (TAA) endovascular stent graft system will gain premarket approval in late 2005